These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 30143243)

  • 1. [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review].
    Papouin B; Mussini C; De Martin E; Guettier C
    Ann Pathol; 2018 Dec; 38(6):338-351. PubMed ID: 30143243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis.
    Reddy HG; Schneider BJ; Tai AW
    Clin Transl Gastroenterol; 2018 Sep; 9(9):180. PubMed ID: 30228268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
    J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management.
    Grover S; Rahma OE; Hashemi N; Lim RM
    Am Soc Clin Oncol Educ Book; 2018 May; 38():13-19. PubMed ID: 30231401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers.
    Sood A; Cole D; Abdollah F; Eilender B; Roumayah Z; Deebajah M; Dabaja A; Alanee S
    Curr Urol Rep; 2018 Jul; 19(9):68. PubMed ID: 29971696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
    Anderson R; Theron AJ; Rapoport BL
    Front Immunol; 2019; 10():2254. PubMed ID: 31616428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
    Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
    J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The "immune checkpoints", how does it work].
    Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
    Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell checkpoint regulators in the heart.
    Grabie N; Lichtman AH; Padera R
    Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.
    Nadeau BA; Fecher LA; Owens SR; Razumilava N
    Semin Liver Dis; 2018 Nov; 38(4):366-378. PubMed ID: 30357774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicities of checkpoint inhibitors: causes and management.
    Postow MA
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):220-222. PubMed ID: 31188813
    [No Abstract]   [Full Text] [Related]  

  • 15. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
    Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
    Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
    Weinmann SC; Pisetsky DS
    Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
    Tetzlaff MT; Jazaeri AA; Torres-Cabala CA; Korivi BR; Landon GA; Nagarajan P; Choksi A; Chen L; Uemura M; Aung PP; Diab A; Sharma P; Davies MA; Amaria R; Prieto VG; Curry JL
    J Cutan Pathol; 2017 Dec; 44(12):1080-1086. PubMed ID: 28901560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors.
    Vozy A; De Martin E; Johnson DB; Lebrun-Vignes B; Moslehi JJ; Salem JE
    Eur J Cancer; 2019 Dec; 123():112-115. PubMed ID: 31678768
    [No Abstract]   [Full Text] [Related]  

  • 19. [Toxicity of immune checkpoints inhibitors].
    Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
    Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Checkpoint Inhibitor-Induced Colitis.
    Bellaguarda E; Hanauer S
    Am J Gastroenterol; 2020 Feb; 115(2):202-210. PubMed ID: 31922959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.